Autolus Therapeutics plc

AUTLNASDAQHealthcare● Active

$1.53

$-0.13(-7.83%)

Market Cap$407199199

P/E Ratio—

52W High$2.7

52W Low$1.175

Avg Volume1.6M

Open$1.66

Beta2.01

Overview

Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Autolus Therapeutics plc (AUTL) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · AUTL · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.09Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$92.6MFull revenue history

Dividend YieldNo DividendDividend history

Shares Outstanding266.1MShares outstanding history

Next EarningsAug 11, 2026Est.Earnings history

Explore Autolus Therapeutics plc Data

Market Cap$407.2M

Analyst Forecast$9 · Buy

DividendsNo Dividend

Revenue$75.6M+646.68%

EarningsEPS $-1.08-24.14%

PE Ratio—

Financial Snapshot

Full Financials

FY 2025Revenue$75.6M▲ +646.68% YoY

202320242025

FY 2025Net Income-$288.2M▼ 30.61% YoY

202320242025

FY 2025EPS$-1.08▼ 24.14% YoY

202320242025

TTM:Revenue: $92.6MNet Income: -$288.8MEPS: $-1.09View income statement →

Analyst Ratings & Price Target

Full Forecast

Buy14 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

12-Month Price Target

$7.60Low

$1.53Current

$8.87Avg Target479.74% upside

$11.00High

Total: 14 · Buy rate: 78.6%

The AUTL analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $8.87, representing +479.74% upside from the current price of $1.53.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

AUTL

Autolus Therapeutics plc

$1.53-7.83%$407.2M #2

ADCT

ADC Therapeutics S.A.

$1.03-21.97%$131.0M #3

ANNX

Annexon, Inc.

$5.29-2.94%$632.7M #4

AURA

Aura Biosciences, Inc.

$6.63-2.50%$425.6M #5

BNTC

Benitec Biopharma Inc.

$10.55-4.52%$276.9M #6

LBRX

LB Pharmaceuticals Inc Common Stock

$28.53-1.28%$818.1M

Stock Performance

Full History

1D-7.83%

1W-14.04%

1M-2.55%

3M+1.32%

YTD-23.12%

1Y-34.89%

5Y-77.70%

About Autolus Therapeutics plc

CEOChristian Martin Itin

IPO DateJun 22, 2018

Employees647

CountryGB

Websiteautolus.com

Autolus Therapeutics plc a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO…

Biotechnology HealthcareNASDAQADRGB

About Stock Overview & Key Data

Autolus Therapeutics plc (AUTL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 22, 2018. As of the latest trading session, AUTL stock price is $1.53, with a market capitalization of $407.2M. The stock has returned -34.89% over the past 12 months and -23.12% year-to-date.

According to 14 Wall Street analysts, the consensus rating for Autolus Therapeutics plc stock is Buy, with an average 12-month price target of $8.87. In fiscal year 2025, Autolus Therapeutics plc reported revenue of $75.6M and net income of -$288.2M. For detailed data — including Autolus Therapeutics plc revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Autolus Therapeutics plc (AUTL) stock price is $1.53. The stock is traded on NASDAQ under the ticker symbol AUTL. The 52-week range is $1.18 – $2.70.

AUTL stock priceAUTL quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice